Literature DB >> 19454099

Peripheral arterial disease.

Kevin Cassar1.   

Abstract

INTRODUCTION: Up to 20% of adults aged over 55 years have detectable peripheral arterial disease of the legs, but this may cause symptoms of intermittent claudication in only a small proportion of affected people. The main risk factors are smoking and diabetes mellitus, but other risk factors for cardiovascular disease are also associated with peripheral arterial disease. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for people with chronic peripheral arterial disease? We searched: Medline, Embase, The Cochrane Library and other important databases up to December 2006. (BMJ Clinical evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 55 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antiplatelet agents, bypass surgery, cilostazol, exercise, pentoxifylline, percutaneous transluminal angioplasty, prostaglandins, smoking cessation, statins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19454099      PMCID: PMC2907782     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  56 in total

1.  PoleStriding exercise and vitamin E for management of peripheral vascular disease.

Authors:  Eileen G Collins; W Edwin Langbein; Cynthia Orebaugh; Christine Bammert; Karla Hanson; Domenic Reda; Lonnie C Edwards; Fred N Littooy
Journal:  Med Sci Sports Exerc       Date:  2003-03       Impact factor: 5.411

2.  Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study.

Authors:  D Vroegindeweij; L D Vos; A V Tielbeek; J Buth; H C vd Bosch
Journal:  Cardiovasc Intervent Radiol       Date:  1997 Nov-Dec       Impact factor: 2.740

3.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

4.  Intermittent claudication. A risk profile from The Framingham Heart Study.

Authors:  J M Murabito; R B D'Agostino; H Silbershatz; W F Wilson
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

5.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

6.  Influence of upper- and lower-limb exercise training on cardiovascular function and walking distances in patients with intermittent claudication.

Authors:  R D Walker; S Nawaz; C H Wilkinson; J M Saxton; A G Pockley; R F Wood
Journal:  J Vasc Surg       Date:  2000-04       Impact factor: 4.268

7.  Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.

Authors:  Sergio Mondillo; Piercarlo Ballo; Riccardo Barbati; Francesco Guerrini; Tiziana Ammaturo; Eustachio Agricola; Monica Pastore; Francesco Borrello; Mirko Belcastro; Andrea Picchi; Renato Nami
Journal:  Am J Med       Date:  2003-04-01       Impact factor: 4.965

8.  Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study.

Authors:  Jean-Pierre Becquemin; Jean-Pierre Favre; Jean Marzelle; Chantal Nemoz; Caroline Corsin; Alain Leizorovicz
Journal:  J Vasc Surg       Date:  2003-03       Impact factor: 4.268

9.  Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial.

Authors:  Emile R Mohler; William R Hiatt; Jeffrey W Olin; Michael Wade; Roger Jeffs; Alan T Hirsch
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  1 in total

1.  The progression rate of peripheral arterial disease in patients with intermittent claudication: a systematic review.

Authors:  A Mizzi; K Cassar; C Bowen; C Formosa
Journal:  J Foot Ankle Res       Date:  2019-08-06       Impact factor: 2.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.